Crossref
TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach
Revue Vétérinaire Clinique · 2026-08 · 61 (3) · 168-169
DOI: 10.1016/j.anicom.2026.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revue Vétérinaire Clinique, 2026-08. Verfasst von L. Aresu.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Aresu, L. (2026). TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach. Revue Vétérinaire Clinique, 61(3), 168-169. https://doi.org/10.1016/j.anicom.2026.06.005
Vancouver
Aresu L. TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach. Revue Vétérinaire Clinique. 2026;61(3):168-169. doi:10.1016/j.anicom.2026.06.005
BibTeX
@article{Aresu2026,
author = {Aresu, L.},
title = {TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach},
journal = {Revue Vétérinaire Clinique},
year = {2026},
volume = {61},
number = {3},
pages = {168--169},
doi = {10.1016/j.anicom.2026.06.005}
}
EUVIMED